FindTrial
Sign In

Clinical evaluation of NK211 and CDDP for cervical cancer.

Clinical evaluation of combined chemotherapy with NK211 and CDDP in patients with cervical cancer.

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221794
Enrollment
Unknown
Registered
2012-05-18
Start date
2012-05-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced and/or recurrent cervical cancer.

Interventions

investigational material(s) Generic name etc : NK211(nogitecan, topotecan)/CDDP INN of investigational material : Therapeutic category code : 424 Antineoplastic preparations extracted from plants Dos

Sponsors

Nippon Kayaku Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients must have recurrent, persistent or stage 4B cervical cancer for which standard curative surgery and/or radiation therapy do not exist or are no longer effective, etc.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Incidence and severity (grade) of the adverse event/toxicity (drug related AE) CTCAE Ver.4.03-JCOG—

Secondary

MeasureTime frame
Antitumor effect RECIST Ver1.1—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026